The real value of this company is not the approval of Adasuve. It;s the way that it is administered with the Staccato system. That is where i think we get the real value. There are over 200 FDA approved compounds that can be used by the Staccato system. What i see is this company being more of a medical device company than a drug company. Companies like pfizer,Merck and J and J will see the effectiveness in the way in which their drug pipeline could fit with the Staccato system and want to aquire Alexza or partner with them.The patents both in Europe and the U.S do not expire till the year 2022 for Staccato. That's right 2022!!! That's 10 years my friend until someone can use or copy such a system for administering or delivering condensation aerosol. It's the newest most non evasive way to administer drugs. No Needles or oral tablet. This is the wave of the future. Like all the shorts say. Mark this post!!!!! When the street falls in love with this company the sky is the limit as far as stock price or faor that matter a buyout.
Agree 100% of each single word! A big company like Merck for example will pay for Adasuve $300 - 400 mill. I belive that in a few weeks we will see bayout or partnership and very fast value increase
of shares to level of $15.00 in several weeks (CE is very close, don't forget 450 mill people in Euro.)